ResVita Bio, a US-based synthetic biology startup, announced on Monday that it has received a USD250,000 Phase 1 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Disease (NIAID).
This grant is to be utilised to develop RVB-101, a genetically engineered cell therapy for the treatment of severe atopic dermatitis. The product is a new type of treatment for severe atopic dermatitis, consisting of genetically engineered cells within a moisturiser formulation.
Dr Amin Zargar, ResVita Bio PhD, chief executive officer, said: "Within a year, we have been honoured to receive two innovation grants from the NIH to develop therapies for both Netherton Syndrome, an orphan disease, and severe atopic dermatitis through our topical cell therapy approach. This is in addition to our Rare Pediatric Disease Designation for Netherton Syndrome from the FDA, setting the stage for the entry of our therapy into the clinic in 2025."
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
TC BioPharm plans Proof of Concept preclinical studies of TCB 008 for treatment of monkey pox
LakeShore Biopharma names new chief executive officer
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
RedHill Biopharma launches Talicia in UAE for H. pylori treatment
RedHill Biopharma reports promising results for opaganib in obesity and diabetes studies
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI